Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie terapii skojarzonej kapsułek D07001-Softgel i Xeloda/TS-1 u pacjentów z zaawansowanym rakiem dróg żółciowych

2 listopada 2026 zaktualizowane przez: InnoPharmax Inc.

Otwarte, wieloośrodkowe badanie fazy II/III nad terapią skojarzoną kapsułek D07001-Softgel i Xeloda/TS-1 u pacjentów z zaawansowanym rakiem dróg żółciowych po niepowodzeniu leczenia gemcytabiną i cisplatyną

The primary objective are:

To assess the safety and tolerability of the combination of D07001-softgel capsules and Xeloda/TS-1.

To evaluate the efficacy of the combination of D07001-softgel capsules and Xeloda/TS-1, as assessed by disease control rate (DCR).

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

This open label, multicenter study will be conducted in 2 stages: a dose-finding stage (Phase IIa) and a dose-expansion stage (Phase IIb/III).

In phase IIa, eligible patients will be assigned to receive oral D07001-softgel on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle (9 doses per cycle) and Xeloda (or TS-1) twice daily on Day 1-14 of a 21-day cycle.

A modified 3+3 dose-finding design method will be applied to identify dose-limiting toxicities (DLTs) and establish the selected dose of D07001-softgel capsules plus Xeloda (or TS-1).

In phase IIb/III,the first 40 subjects (20 subjects per arm) will be randomly allocated in a 1:1 ratio in two arms. Arm A will receive active symptom control (ASC) with the selected dose from dose-finding stage of D07001-softgel capsules and Xeloda (or TS-1), in 21-day cycles. In arm B, subjects will receive ASC with mFOLFOX treatment. After the last subject of first 40 subjects will be completed the visit in the end of treatment, an adaptive interim analysis will be planned to re-estimate the required sample size based on the result of DCR if needed. The sponsor team will determine whether the study will be continued or stopped for futility.

If the study continues to proceed, the total subject number will be based on the decision from the results of interim study. The rest of subjects will be randomized to receive the combination of study drug or active-control drug with the same allocation in two arms. Both groups will continue the therapy until disease progression, withdrawn consent, or when another treatment discontinuation criterion is met.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

19

Faza

  • Faza 2
  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Kaohsiung City, Tajwan, 807
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Taichung, Tajwan, 404
        • China Medical University Hospital
      • Taipei, Tajwan
        • Taipei Veterans General Hospital
      • Taipei, Tajwan
        • National Taiwan University Cancer Center
      • Taipei, Tajwan
        • National Taiwan University Hospotal

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Male or female patients aged 18 years or older at screening (aged 20 years or older in Taiwan)

  2. Histopathological or cytologic diagnosis of unresectable metastatic or locally advanced BTC (cholangiocarcinoma, gallbladder cancer or ampullary carcinoma)

  3. Subject must have failed from first line gemcitabine and cisplatin-based chemotherapy

  4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-1

  5. Life expectancy is >12 weeks

  6. Adequate bone marrow function, demonstrated by:

    1. Absolute neutrophil count (ANC) ≥1,500 cell/mm3
    2. Platelet count ≥ 100,000 cells/mm3
    3. Hemoglobin ≥ 9 g/dL
  7. Adequate liver function, demonstrated by:

    1. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 x upper limit of normal (ULN), or ≤5.0 x ULN in the case of liver metastases
    2. Total bilirubin ≤1.5 x ULN
    3. Albumin ≥3.0 g/dL
    4. International normalized ratio (INR) <1.5
  8. Adequate renal function, demonstrated by:

    1. Serum creatinine ≤1.5 x ULN
    2. Creatinine clearance ≥ 50mL/min calculated by Cockcroft-Gault formula or eGFR ≥ 50mL/min/1.73m2 by 2021 CKD-EPI Creatinine Equation
  9. A negative serum pregnancy test at screening and is not breastfeeding in woman of childbearing potential

  10. Women of childbearing potential or male subjects must use a medically acceptable form of contraception as 2 barrier methods (e.g., combination of condom, diaphragm, or intrauterine device), hormonal contraception (estrogen or progesterone agents) or 1 barrier method in combination with spermicide. Birth control is required 1 month prior to screening, for the duration of their study participation, and for 1 month after the end of the study; female partners of male subjects must adhere to the same birth control methods.

  11. Provision of a signed and dated written Informed Consent Form (ICF) prior to any study specific procedures

  12. Subject is willing to comply with protocol-required visit schedule and visit requirements

  13. No more than 60 days have elapsed between completion of the prior line of chemotherapy or CCRT and enrollment

  14. Subject has not received other chemotherapy since first-line treatment

Exclusion Criteria:

  1. Have prior chemotherapy regimen other than first line gemcitabine and cisplatin-based therapy for unresectable metastatic or locally advanced BTC Note: prior fluoropyrimidine base (including capecitabine, carmofur (HCFU), doxifluridine, fluorouracil (5-FU), and tegafur) chemotherapy (including fluoropyrimidine monotherapy or combination therapy) are allowed as postsurgical adjuvant therapy.
  2. Diagnosis of active malignancy other than BTC within the past 2 years, except nonmelanoma skin carcinoma and carcinoma-in-situ of uterine cervix treated with curative intent
  3. Prior discontinuation of gemcitabine because of pulmonary or hepatic toxicity or hemolytic uremic syndrome (HUS) or hypersensitivity, allergic reaction, or intolerance
  4. Known or suspected hypersensitivity to capecitabine, tegafur, gimeracil, oteracil potassium, oxaliplatin or other platinum compounds, leucovorin products, folic acid or folinic acid, 5-fluorouracil or their excipients.
  5. Prior discontinuation of fluoropyrimidine because of any unexpected or severe reaction.
  6. Treatment with brivudine, sorivudine, or its chemically-related analogs ≤ 28 days prior to the date of enrollment.
  7. Under flucytosine treatment.
  8. Residual toxicity from prior chemotherapy or CCRT that is Grade ≥2 (residual Grade 2 neuropathy and alopecia are permitted)
  9. Any GI disorder which would significantly impede absorption of an oral agent
  10. Known brain or leptomeningeal metastases
  11. Major surgery or definitive ablation-intent (excluding palliative radiotherapy for bone metastasis) radiation therapy within the past 28 days
  12. Any active disease or condition that would not permit compliance with the protocol
  13. Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, congestive heart failure, or New York Heart Association [NYHA] Grade 2 or greater), or uncontrolled serious cardiac arrhythmia
  14. Have documented cerebrovascular disease. Subjects with the disease may be excluded, but if the investigator assesses that they are asymptomatic or well controlled could be enrolled.
  15. Have a seizure disorder not controlled on medication (based on decision of Investigator)
  16. Received an investigational agent within 28 days of enrollment
  17. Have an uncontrolled active viral, bacterial, or systemic fungal infection
  18. Known human immunodeficiency virus (HIV) infection
  19. Have HBsAg (hepatitis B surface antigen) positive with HBV-DNA ≥2000 copies/ml and/or anti-HCV antibody (HCV) positive with HCV-RNA positive.
  20. Received yellow fever vaccine or other live attenuated vaccine(s) within the 4 weeks prior to screening
  21. History of drug or alcohol abuse within last year
  22. Have any other serious medical condition that, in the Investigator's medical opinion, would preclude safe participation in, and compliance with, a clinical trial

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Zadanie sekwencyjne
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Phase IIa:Dose-Finding Stage

Level -5: 20 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).

Level -4: 40 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).

Level -3: 60 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).

Level -2: 80 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).

Level -1 (starting dose): 100 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).

Level 1: 100 mg D07001-softgel capsules plus 800 mg/m^2 Xeloda (or 30/40/50 mg TS-1).

Level 2: 100 mg D07001-softgel capsules plus 1000 mg/m^2 Xeloda (or 40/50/60 mg TS-1).

D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).

Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)

Inne nazwy:
  • Grupa eksperymentalna
Aktywny komparator: Phase IIb/III: Dose Expansion Stage

ASC+ D07001-softgel capsules plus Xeloda (or TS-1)

ASC+mFOLFOX (5-FU+Oxalipatin+folinic acid)

D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).

Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)

Inne nazwy:
  • Grupa eksperymentalna

intravenous infusion on Day 1 for 14-day cycle

Inne nazwy:
  • Grupa kontrolna

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Incidence of adverse events (AEs)/ serious adverse event (SAEs)
Ramy czasowe: From date of informed consent to 30-day follow-up visit for each subject

AEs will be assessed via the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03

From date of informed consent to 30-day follow-up visit for each subject
To assess disease control rate (DCR)
Ramy czasowe: From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months

To assess DCR, the percentage of treatment patients who achieved CR, PR, or SD.

From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Phase IIa and IIb: Pharmacokinetics (PK) of gemcitabine (dFdC), difluorodeoxyuridine (dFdU), capecitabine, 5-FU, Tegafur, Gimeracil, and Oteracil potassium
Ramy czasowe: Cycle 1 Days 1, 8, and 12 (each cycle is 21 days)

PK parameters (Peak Plasma Concentration (Cmax)) of gemcitabine and Xeloda or TS-1 will be evaluated

Cycle 1 Days 1, 8, and 12 (each cycle is 21 days)
Quality of life (QOL) will be assessed using the EORTC questionnaires
Ramy czasowe: Cycle 1 Days 1, and date of withdraw the study (assessed up to 24 months) for each subject (each cycle is 21 days)

To access healthrelated quality of life of cancer patients participating in clinical trial.

Cycle 1 Days 1, and date of withdraw the study (assessed up to 24 months) for each subject (each cycle is 21 days)
To assess Progression-free survival (PFS)
Ramy czasowe: From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months

To assess PFS, the time from treatment assignment/randomization until objective tumor progression or death

From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months
To assess Objective response rate (ORR)
Ramy czasowe: From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months

To assess ORR, the proportion of treated patients who achieved a BOR of CR or PR.

From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months
To assess overall survival (OS)
Ramy czasowe: The survival follow-ups will follow every 6 weeks from date of discontinued study drug for up to 24 months till the death of the subject or closure of the study.

To assess OS, the time from treatment assignment/randomization until death from any case

The survival follow-ups will follow every 6 weeks from date of discontinued study drug for up to 24 months till the death of the subject or closure of the study.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Główny śledczy: Li-Tzong Chen, Ph.D, National Institute of Cancer Research

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

29 marca 2022

Zakończenie podstawowe (Rzeczywisty)

31 lipca 2025

Ukończenie studiów (Rzeczywisty)

31 lipca 2025

Daty rejestracji na studia

Pierwszy przesłany

7 września 2021

Pierwszy przesłany, który spełnia kryteria kontroli jakości

23 września 2021

Pierwszy wysłany (Rzeczywisty)

4 października 2021

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

4 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

2 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • Inno-GO-05

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .